332 related articles for article (PubMed ID: 36354315)
1. Anthracycline chemotherapy, vascular dysfunction and cognitive impairment: burgeoning topics and future directions.
Maurer GS; Clayton ZS
Future Cardiol; 2023 Sep; 19(11):547-566. PubMed ID: 36354315
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.
Bhagat A; Kleinerman ES
Adv Exp Med Biol; 2020; 1257():181-192. PubMed ID: 32483740
[TBL] [Abstract][Full Text] [Related]
3. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Prevent Cardiotoxicity.
Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
[TBL] [Abstract][Full Text] [Related]
5. Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy.
Dozic S; Howden EJ; Bell JR; Mellor KM; Delbridge LMD; Weeks KL
Cells; 2023 May; 12(9):. PubMed ID: 37174712
[TBL] [Abstract][Full Text] [Related]
6. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
7. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
10. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.
Sadurska E
Pediatr Cardiol; 2015 Aug; 36(6):1112-9. PubMed ID: 25939787
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotection in cancer therapy: novel insights with anthracyclines.
Raber I; Asnani A
Cardiovasc Res; 2019 Apr; 115(5):915-921. PubMed ID: 30726931
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity.
Tantawy M; Pamittan FG; Singh S; Gong Y
Clin Transl Sci; 2021 Jan; 14(1):36-46. PubMed ID: 32770710
[TBL] [Abstract][Full Text] [Related]
13. Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.
Chen JJ; Wu PT; Middlekauff HR; Nguyen KL
Am J Physiol Heart Circ Physiol; 2017 Feb; 312(2):H213-H222. PubMed ID: 27923793
[TBL] [Abstract][Full Text] [Related]
14. Rational and design of SATRACD study: detecting subclinical anthracycline therapy related cardiac dysfunction in low income country.
Zhang W; Azibani F; Okello E; Kayima J; Walusansa V; Orem J; Sliwa K
Afr Health Sci; 2021 Jun; 21(2):647-654. PubMed ID: 34795719
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.
Bassareo PP; Monte I; Romano C; Deidda M; Piras A; Cugusi L; Coppola C; Galletta F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e55-e63. PubMed ID: 27755243
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients.
Stansfeld A; Radia U; Goggin C; Mahalingam P; Benson C; Napolitano A; Jones RL; Rosen SD; Karavasilis V
Expert Opin Pharmacother; 2022 Oct; 23(14):1641-1650. PubMed ID: 36102190
[TBL] [Abstract][Full Text] [Related]
17. A bench to bedside perspective on anthracycline chemotherapy-mediated cardiovascular dysfunction: challenges and opportunities. A symposium review.
Clayton ZS; Ade CJ; Dieli-Conwright CM; Mathelier HM
J Appl Physiol (1985); 2022 Dec; 133(6):1415-1429. PubMed ID: 36302155
[TBL] [Abstract][Full Text] [Related]
18. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
[TBL] [Abstract][Full Text] [Related]
19. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Vejpongsa P; Yeh ET
J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced cardiomyopathy.
Higgins AY; O'Halloran TD; Chang JD
Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
